Status:

RECRUITING

Use of Sensory Substitution to Improve Arm Control After Stroke

Lead Sponsor:

Marquette University

Collaborating Sponsors:

Medical College of Wisconsin

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Stroke

Proprioceptive Disorders

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

Supplementing or augmenting sensory information to those who have lost proprioception after stroke could help improve functional control of the arm. Thirty subjects will be recruited to a single site ...

Detailed Description

This study has two distinct aims to be addressed in a longitudinal study spanning 24 days. Aim 1 tests the hypothesis that stroke survivors can improve motor control of their contralesional arm throu...

Eligibility Criteria

Inclusion

  • stroke survivors who can perform our stabilization and grip modulation tasks and who
  • had a single ischemic or hemorrhagic stroke of the middle cerebral artery (MCA) in the chronic state of recovery (\> 6 months post-stroke).
  • ability to give informed consent and be able to follow two-stage instructions.
  • mild-to-moderate motor impairment as assessed using the upper extremity (UE) portion of the Fugl-Meyer Motor Assessment (FM); i.e., UE-FM score between 28 and 50 (inclusive) out of a possible 66.
  • proprioceptive deficit at the elbow in the more involved (contralesional) arm.
  • preserved tactile sensation in either the ipsilesional arm and/or thigh.
  • a minimal active wrist extension of 5°.

Exclusion

  • Inability of subjects to give informed consent or follow two-stage instructions.
  • subjects with a bleeding disorder.
  • subjects with fixed contractures or a history of tendon transfer in the involved limb.
  • subjects with a diagnosis of myasthenia gravis, amyotrophic lateral sclerosis or any disease that might interfere with neuromuscular function.
  • subjects who are currently using or under the influence of aminoglycoside antibiotics, curare-like agents, or other agents that may interfere with neuromuscular function.
  • subjects with a history of epilepsy.
  • history of other psychiatric co-morbidities (e.g. schizophrenia).
  • malignant or benign intra-axial neoplasms.
  • concurrent illness limiting the capacity to conform to study requirements.
  • Cardiac pacemaker, cardiac arrhythmia or history of significant cardiovascular or respiratory compromise.
  • subjects with profound atrophy or excessive weakness of muscles in the target area(s) of testing.
  • subjects with a systemic infection.

Key Trial Info

Start Date :

July 17 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 31 2026

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03298243

Start Date

July 17 2023

End Date

May 31 2026

Last Update

September 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Marquette University

Milwaukee, Wisconsin, United States, 53233